[go: up one dir, main page]

NO20014519D0 - Apomorfin- og sildenafilpreparat - Google Patents

Apomorfin- og sildenafilpreparat

Info

Publication number
NO20014519D0
NO20014519D0 NO20014519A NO20014519A NO20014519D0 NO 20014519 D0 NO20014519 D0 NO 20014519D0 NO 20014519 A NO20014519 A NO 20014519A NO 20014519 A NO20014519 A NO 20014519A NO 20014519 D0 NO20014519 D0 NO 20014519D0
Authority
NO
Norway
Prior art keywords
apomorphine
sildenafil
administered
treatment
preparation
Prior art date
Application number
NO20014519A
Other languages
English (en)
Other versions
NO324511B1 (no
NO20014519L (no
Inventor
Ragab El-Rashidy
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of NO20014519D0 publication Critical patent/NO20014519D0/no
Publication of NO20014519L publication Critical patent/NO20014519L/no
Publication of NO324511B1 publication Critical patent/NO324511B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014519A 1999-03-16 2001-09-17 Anvendelse av apomorfin og sildenafil for fremstilling av et medikament for behandling av erektil dysfunksjon NO324511B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/270,035 US6087362A (en) 1999-03-16 1999-03-16 Apomorphine and sildenafil composition
PCT/US2000/006654 WO2000054774A1 (en) 1999-03-16 2000-03-14 Apomorphine and sildenafil composition

Publications (3)

Publication Number Publication Date
NO20014519D0 true NO20014519D0 (no) 2001-09-17
NO20014519L NO20014519L (no) 2001-10-25
NO324511B1 NO324511B1 (no) 2007-11-05

Family

ID=23029614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014519A NO324511B1 (no) 1999-03-16 2001-09-17 Anvendelse av apomorfin og sildenafil for fremstilling av et medikament for behandling av erektil dysfunksjon

Country Status (21)

Country Link
US (1) US6087362A (no)
EP (1) EP1173178B1 (no)
JP (1) JP2002539163A (no)
CN (1) CN1350454A (no)
AT (1) ATE302003T1 (no)
AU (1) AU3744500A (no)
BR (1) BR0009016A (no)
CA (1) CA2367605A1 (no)
CZ (1) CZ20013344A3 (no)
DE (1) DE60022021T2 (no)
DK (1) DK1173178T3 (no)
ES (1) ES2244418T3 (no)
HU (1) HUP0200549A3 (no)
IL (1) IL145487A0 (no)
MX (1) MXPA01009332A (no)
NO (1) NO324511B1 (no)
NZ (1) NZ514464A (no)
PL (1) PL350313A1 (no)
PT (1) PT1173178E (no)
WO (1) WO2000054774A1 (no)
ZA (1) ZA200107920B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
DK1315502T3 (da) * 2000-08-30 2010-07-19 Unimed Pharmaceuticals Llc Fremgangsmåde til behandling af erektil dysfunktion og til forøgelse af mænds libido
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
WO2002062315A1 (en) * 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AR036674A1 (es) * 2001-08-28 2004-09-29 Schering Corp Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
EP1496915A1 (en) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
PT1750766E (pt) * 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
RS20070166A (sr) * 2004-10-20 2008-09-29 Endorecherche Inc., Prekursori seksualnih steroida sami ili u kombinaciji sa selektivnim modulatorom estrogenskog receptora i/ili sa inhibitorom cgmp fosfodiesteraze tipa 5 za prevenciju ili tretman isušenosti vaginalne sluzokože i seksualne disfunkcije kod žena u postmenopauzi
PL2450041T3 (pl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
SG174079A1 (en) * 2007-02-12 2011-09-29 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction
US20080261991A1 (en) * 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Reducing Side Effects of Tramadol
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
EP2238168B8 (en) * 2007-12-26 2014-07-23 Biotest AG Agents targeting cd138 and uses thereof
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
ES2526433T3 (es) * 2007-12-26 2015-01-12 Biotest Ag Inmunoconjugados dirigidos a CD138 y usos de los mismos
EP2240516B1 (en) * 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
US20090246298A1 (en) * 2008-03-31 2009-10-01 Ceola P. Steele Viagra
US20100184722A1 (en) * 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
MX2011011684A (es) * 2009-05-06 2012-01-20 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2765291C (en) * 2009-06-12 2016-03-08 Adagio Pharmaceuticals Ltd. Sublingual apomorphine
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
EP3285771B1 (en) 2015-04-21 2025-02-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
PT758895E (pt) * 1994-04-22 2000-05-31 Univ Kingston Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
BR9809848A (pt) * 1997-05-19 2000-06-27 Zonagen Inc Composição
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
PT1173178E (pt) 2005-11-30
ES2244418T3 (es) 2005-12-16
PL350313A1 (en) 2002-12-02
WO2000054774A1 (en) 2000-09-21
EP1173178B1 (en) 2005-08-17
ZA200107920B (en) 2003-03-26
CA2367605A1 (en) 2000-09-21
NO324511B1 (no) 2007-11-05
JP2002539163A (ja) 2002-11-19
DE60022021T2 (de) 2006-06-08
HUP0200549A2 (hu) 2002-07-29
DE60022021D1 (de) 2005-09-22
IL145487A0 (en) 2002-06-30
BR0009016A (pt) 2002-04-16
MXPA01009332A (es) 2002-06-21
EP1173178A4 (en) 2002-09-04
DK1173178T3 (da) 2005-11-07
ATE302003T1 (de) 2005-09-15
NO20014519L (no) 2001-10-25
CZ20013344A3 (cs) 2002-08-14
NZ514464A (en) 2004-01-30
US6087362A (en) 2000-07-11
CN1350454A (zh) 2002-05-22
EP1173178A1 (en) 2002-01-23
HUP0200549A3 (en) 2004-07-28
AU3744500A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
NO20014519L (no) Apomorfin- og sildenafilpreparat
JP2006514092A5 (no)
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
JP2002540148A5 (no)
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
JP2001316293A5 (no)
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
CO5170404A1 (es) Terapia para melanomas
HK1133829A (en) Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
PT1265629E (pt) Utilizacao da hormona de crescimento em dose baixa
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante